Skip to main content
IVA
NASDAQ Life Sciences

Inventiva Seeks Shareholder Approval for Extensive Capital Raises & Refinancing Measures

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$3.83
Mkt Cap
$833.291M
52W Low
$2.854
52W High
$7.983
Market data snapshot near publication time

Summary

Inventiva S.A. has mailed its proxy card for a June 30, 2026, shareholder meeting, seeking approval for numerous proposals including significant capital increases, an At-The-Market program, and a resolution regarding its shareholders' equity being below half its share capital.


Key Events

  • Shareholder Meeting Scheduled

    Inventiva will hold an Ordinary and Extraordinary General Meeting on June 30, 2026, to vote on 40 proposals, including critical financial and governance matters.

  • Extensive Capital Increase Authorizations

    Shareholders will vote on multiple delegations of authority to the Board to increase share capital through various means, including public offerings, private placements, and an At-The-Market (ATM) program, enabling significant future dilution.

  • Resolution for Equity Deficit

    A critical proposal addresses the company's shareholders' equity falling below half its share capital, a mandatory resolution under French commercial law following previous disclosures of financial distress.

  • European Investment Bank Warrants

    Shareholders will vote on the issuance of share subscription warrants to the European Investment Bank, a component of the company's refinancing efforts.


Analysis

This proxy filing details the critical shareholder votes required to implement Inventiva's previously announced refinancing package and address its severe financial distress, including a "going concern" warning. The proposals authorize the Board to issue substantial new equity, including through an At-The-Market (ATM) program and warrants to the European Investment Bank, which will be highly dilutive but are essential for the company's continued operations. Shareholders will also vote on a resolution concerning the company's equity falling below half its share capital, a mandatory step under French law.

At the time of this filing, IVA was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $833.3M. The 52-week trading range was $2.85 to $7.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IVA - Latest Insights

IVA
Jun 03, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
9
IVA
Jun 02, 2026, 9:40 PM EDT
Filing Type: 6-K
Importance Score:
9
IVA
Jun 02, 2026, 4:20 PM EDT
Filing Type: 424B5
Importance Score:
9
IVA
Jun 02, 2026, 4:17 PM EDT
Filing Type: FWP
Importance Score:
9
IVA
Jun 02, 2026, 6:00 AM EDT
Filing Type: F-3ASR
Importance Score:
7
IVA
May 26, 2026, 4:20 PM EDT
Filing Type: 6-K
Importance Score:
9
IVA
May 22, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
IVA
Apr 22, 2026, 4:23 PM EDT
Filing Type: 6-K
Importance Score:
7
IVA
Apr 08, 2026, 9:01 AM EDT
Filing Type: 20-F
Importance Score:
9
IVA
Feb 17, 2026, 6:10 AM EST
Filing Type: 6-K
Importance Score:
8